Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fortress Biotech (FBIO – Research Report), GoodRx Holdings (GDRX – Research Report) and Adaptimmune Therapeutics (ADAP – Research Report).
Fortress Biotech (FBIO)
Roth MKM analyst Jason Wittes reiterated a Buy rating on Fortress Biotech today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.74, close to its 52-week low of $1.24.
According to TipRanks.com, Wittes is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fortress Biotech with a $13.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
GoodRx Holdings (GDRX)
Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on GoodRx Holdings today and set a price target of $7.00. The company’s shares closed last Wednesday at $7.27.
According to TipRanks.com, Hettenbach is ranked #952 out of 8856 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GoodRx Holdings with a $9.04 average price target, representing a 35.7% upside. In a report issued on May 13, Truist Financial also maintained a Hold rating on the stock.
Adaptimmune Therapeutics (ADAP)
In a report released today, Peter Lawson from Barclays maintained a Sell rating on Adaptimmune Therapeutics, with a price target of $1.00. The company’s shares closed last Wednesday at $1.24.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Currently, the analyst consensus on Adaptimmune Therapeutics is a Moderate Buy with an average price target of $3.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FBIO:
- Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
- Fortress Biotech announces first patient dosed in Phase 2 study of triplex
- Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
